Kymera Therapeutics (KYMR) Change in Accured Expenses (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Change in Accured Expenses of -$7.2 million for Q1 2026, up 38.33% year-over-year from -$5.2 million in Q1 2025, and down 152.77% quarter-over-quarter from $13.7 million in Q4 2025.
Kymera Therapeutics (KYMR) Change in Accured Expenses (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Change in Accured Expenses for 8 consecutive years, with -$7.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 38.33% year-over-year to -$7.2 million; the TTM figure through Mar 2026 stood at $11.9 million (up 50.53% YoY), while the FY2025 annual figure was $7.4 million, up 76.72% from the prior year.
- Change in Accured Expenses retreated to -$7.2 million in Q1 2026 per KYMR's latest filing, from $13.7 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $13.7 million in Q4 2025 and bottomed at -$15.4 million in Q1 2024.
- Historically, Change in Accured Expenses has averaged $709235.3 across 5 years, with a median of $2.7 million in 2024.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses tumbled 1069.36% — and 2023, when it soared 578.32%.
- Kymera Therapeutics' Change in Accured Expenses stood at $2.8 million in 2022, then soared by 139.02% to $6.8 million in 2023, then surged by 32.81% to $9.0 million in 2024, then surged by 51.43% to $13.7 million in 2025, then sank by 152.77% to -$7.2 million in 2026.
- Business Quant data shows KYMR's Change in Accured Expenses at -$7.2 million in Q1 2026, $13.7 million in Q4 2025, and $664000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 55.78 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 212.44 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 61.62 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - | 13.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.49 Mn |
| Jun 30, 2026 | 13.49 Mn |
| Mar 31, 2026 | -7.21 Mn |
| Mar 31, 2026 | -7.21 Mn |
| Dec 31, 2025 | 13.66 Mn |
| Dec 31, 2025 | 13.66 Mn |
| Sep 30, 2025 | 664,000.00 |
| Sep 30, 2025 | 664,000.00 |
| Jun 30, 2025 | 4.75 Mn |
| Jun 30, 2025 | 4.75 Mn |
| Mar 31, 2025 | -11.69 Mn |
| Mar 31, 2025 | -11.69 Mn |
| Dec 31, 2024 | 9.02 Mn |
| Dec 31, 2024 | 9.02 Mn |
| Sep 30, 2024 | 2.75 Mn |
| Sep 30, 2024 | 2.75 Mn |
| Jun 30, 2024 | 7.80 Mn |
| Jun 30, 2024 | 7.80 Mn |
| Mar 31, 2024 | -15.39 Mn |
| Mar 31, 2024 | -15.39 Mn |